- 現金殖利率: 1.69%、總殖利率: 1.69%、5年平均現金配發率: 25.8%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 (10) | 15.67 | 35.79 | 4.65 | 34.39 | 0.00 | 0 | 29.67 | -1.03 | 0.00 | 0 | 29.67 | -1.03 |
| 2022 (9) | 11.54 | 110.97 | 3.46 | 79.27 | 0.00 | 0 | 29.98 | -15.02 | 0.00 | 0 | 29.98 | -15.02 |
| 2021 (8) | 5.47 | 29.62 | 1.93 | 451.43 | 0.00 | 0 | 35.28 | 325.42 | 0.00 | 0 | 35.28 | 325.42 |
| 2020 (7) | 4.22 | 54.01 | 0.35 | 0 | 0.00 | 0 | 8.29 | 0 | 0.00 | 0 | 8.29 | 0 |
| 2019 (6) | 2.74 | 552.38 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2018 (5) | 0.42 | 366.67 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2017 (4) | 0.09 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2016 (3) | -0.63 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 24Q3 (20) | 5.98 | 17.49 | 25.63 | 6.79 | 36.35 | 52.93 | 15.03 | 66.08 | 5.92 |
| 24Q2 (19) | 5.09 | 28.54 | 4.95 | 4.98 | 32.45 | -3.86 | 9.05 | 128.54 | -4.03 |
| 24Q1 (18) | 3.96 | 158.82 | -13.54 | 3.76 | 2792.31 | -27.13 | 3.96 | -74.81 | -13.54 |
| 23Q4 (17) | 1.53 | -67.86 | 139.06 | 0.13 | -97.07 | -85.23 | 15.72 | 10.78 | 35.63 |
| 23Q3 (16) | 4.76 | -1.86 | -40.28 | 4.44 | -14.29 | -44.36 | 14.19 | 50.48 | 29.47 |
| 23Q2 (15) | 4.85 | 5.9 | 284.92 | 5.18 | 0.39 | 247.65 | 9.43 | 105.9 | 217.51 |
| 23Q1 (14) | 4.58 | 615.62 | 166.28 | 5.16 | 486.36 | 180.43 | 4.58 | -60.48 | 166.28 |
| 22Q4 (13) | 0.64 | -91.97 | -35.35 | 0.88 | -88.97 | -29.03 | 11.59 | 5.75 | 110.73 |
| 22Q3 (12) | 7.97 | 532.54 | 494.78 | 7.98 | 435.57 | 356.0 | 10.96 | 269.02 | 141.41 |
| 22Q2 (11) | 1.26 | -26.74 | -8.7 | 1.49 | -19.02 | -18.13 | 2.97 | 72.67 | -7.48 |
| 22Q1 (10) | 1.72 | 73.74 | -7.03 | 1.84 | 48.39 | -15.6 | 1.72 | -68.73 | -7.03 |
| 21Q4 (9) | 0.99 | -26.12 | -24.43 | 1.24 | -29.14 | -10.14 | 5.50 | 21.15 | 30.33 |
| 21Q3 (8) | 1.34 | -2.9 | 16.52 | 1.75 | -3.85 | 28.68 | 4.54 | 41.43 | 55.48 |
| 21Q2 (7) | 1.38 | -25.41 | 12.2 | 1.82 | -16.51 | 34.81 | 3.21 | 73.51 | 81.36 |
| 21Q1 (6) | 1.85 | 41.22 | 242.59 | 2.18 | 57.97 | 115.84 | 1.85 | -56.16 | 242.59 |
| 20Q4 (5) | 1.31 | 13.91 | 125.86 | 1.38 | 1.47 | 84.0 | 4.22 | 44.52 | 54.01 |
| 20Q3 (4) | 1.15 | -6.5 | 0.0 | 1.36 | 0.74 | 0.0 | 2.92 | 64.97 | 0.0 |
| 20Q2 (3) | 1.23 | 127.78 | 0.0 | 1.35 | 33.66 | 0.0 | 1.77 | 227.78 | 0.0 |
| 20Q1 (2) | 0.54 | -6.9 | 0.0 | 1.01 | 34.67 | 0.0 | 0.54 | -80.29 | 0.0 |
| 19Q4 (1) | 0.58 | 0.0 | 0.0 | 0.75 | 0.0 | 0.0 | 2.74 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/11 | 10.61 | -43.73 | -6.55 | 171.21 | 9.85 | 41.32 | N/A | - | ||
| 2024/10 | 18.85 | 58.82 | 106.76 | 160.6 | 11.13 | 43.97 | N/A | 主係本月血癌用藥Lenalidomide於美國市場銷售量較去年同期增加所致 | ||
| 2024/9 | 11.87 | -10.45 | 7.85 | 141.75 | 4.7 | 52.34 | 0.76 | - | ||
| 2024/8 | 13.25 | -51.31 | 11.85 | 129.88 | 4.42 | 51.61 | 0.77 | - | ||
| 2024/7 | 27.22 | 144.35 | 18.97 | 116.63 | 3.63 | 53.89 | 0.74 | - | ||
| 2024/6 | 11.14 | -28.25 | 0.98 | 89.41 | -0.27 | 47.43 | 0.8 | - | ||
| 2024/5 | 15.53 | -25.22 | 17.48 | 78.27 | -0.45 | 47.79 | 0.8 | - | ||
| 2024/4 | 20.76 | 80.46 | 2.93 | 62.74 | -4.07 | 42.79 | 0.89 | - | ||
| 2024/3 | 11.51 | 9.37 | -19.55 | 41.98 | -7.19 | 41.98 | 0.89 | - | ||
| 2024/2 | 10.52 | -47.29 | -3.13 | 30.48 | -1.48 | 44.2 | 0.85 | - | ||
| 2024/1 | 19.96 | 45.41 | -0.59 | 19.96 | -0.59 | 45.03 | 0.83 | - | ||
| 2023/12 | 13.72 | 20.91 | 7.98 | 169.58 | 15.89 | 34.19 | 1.1 | - | ||
| 2023/11 | 11.35 | 24.5 | 5.94 | 155.86 | 16.64 | 31.47 | 1.2 | - | ||
| 2023/10 | 9.12 | -17.15 | 9.93 | 144.51 | 17.57 | 31.97 | 1.18 | - | ||
| 2023/9 | 11.0 | -7.12 | -67.14 | 135.39 | 18.12 | 45.73 | 0.86 | 本月營收較去年同期減少主係因去年血癌用藥集中於九月出貨基期較高，今年分散逐季出貨後，累計營收仍較去年同期成長。 | ||
| 2023/8 | 11.85 | -48.21 | 18.86 | 124.38 | 53.32 | 45.76 | 0.86 | 本年累計營業收入較去年同期增長係因本年度血癌用藥Lenalidomide於美國市場銷售量增加所致。 | ||
| 2023/7 | 22.88 | 107.4 | 119.22 | 112.54 | 58.15 | 47.13 | 0.83 | 主係血癌用藥Lenalidomide於美國市場銷售量增加所致 | ||
| 2023/6 | 11.03 | -16.52 | 5.99 | 89.66 | 47.66 | 44.42 | 0.88 | - | ||
| 2023/5 | 13.22 | -34.48 | 51.8 | 78.63 | 56.28 | 47.69 | 0.82 | 主係美國市場客戶戒毒癮藥及血癌用藥Lenalidomide銷量增加所致 | ||
| 2023/4 | 20.17 | 41.04 | 101.89 | 65.41 | 57.21 | 45.33 | 0.86 | 美國市場客戶血癌用藥Lenalidomide補貨所致 | ||
| 2023/3 | 14.3 | 31.7 | 20.52 | 45.24 | 43.09 | 45.24 | 0.79 | - | ||
| 2023/2 | 10.86 | -45.91 | 5.53 | 30.94 | 56.66 | 43.65 | 0.82 | 一月份美國市場客戶血癌用藥Lenalidomide補貨所致 | ||
| 2023/1 | 20.08 | 57.96 | 112.28 | 20.08 | 112.28 | 43.5 | 0.82 | 美國市場客戶血癌用藥Lenalidomide補貨所致 | ||
| 2022/12 | 12.71 | 18.63 | 39.03 | 146.33 | 15.68 | 31.72 | 1.05 | - | ||
| 2022/11 | 10.71 | 29.18 | 8.61 | 133.62 | 14.19 | 52.5 | 0.63 | - | ||
| 2022/10 | 8.29 | -75.23 | -4.48 | 122.9 | 14.7 | 51.75 | 0.64 | - | ||
| 2022/9 | 33.49 | 235.96 | 230.63 | 114.61 | 16.4 | 53.89 | 0.56 | 血癌用藥Lenalidomide本期在美國上市銷售 | ||
| 2022/8 | 9.97 | -4.48 | 6.38 | 81.12 | -8.16 | 30.81 | 0.98 | - | ||
| 2022/7 | 10.44 | 0.27 | -5.79 | 71.15 | -9.88 | 29.55 | 1.02 | - | ||
| 2022/6 | 10.41 | 19.55 | -9.51 | 60.72 | -10.55 | 29.1 | 1.07 | - | ||
| 2022/5 | 8.71 | -12.87 | -24.72 | 50.31 | -10.77 | 30.56 | 1.02 | - | ||
| 2022/4 | 9.99 | -15.8 | -13.67 | 41.61 | -7.16 | 32.15 | 0.97 | - | ||
| 2022/3 | 11.87 | 15.32 | 7.83 | 31.61 | -4.9 | 31.61 | 1.0 | - | ||
| 2022/2 | 10.29 | 8.78 | 1.27 | 19.75 | -11.2 | 28.89 | 1.09 | - | ||
| 2022/1 | 9.46 | 3.46 | -21.7 | 9.46 | -21.7 | 28.46 | 1.11 | - | ||
| 2021/12 | 9.14 | -7.32 | -9.59 | 126.15 | 17.58 | 27.69 | 1.11 | - | ||
| 2021/11 | 9.86 | 13.6 | 3.04 | 117.01 | 22.16 | 28.67 | 1.07 | - | ||
| 2021/10 | 8.68 | -14.27 | -15.15 | 107.14 | 24.28 | 28.18 | 1.09 | - | ||
| 2021/9 | 10.13 | 8.1 | -0.76 | 98.46 | 29.59 | 30.58 | 0.84 | - | ||
| 2021/8 | 9.37 | -15.42 | 25.26 | 88.33 | 34.32 | 31.95 | 0.8 | - | ||
| 2021/7 | 11.08 | -3.67 | -0.8 | 78.96 | 35.48 | 34.14 | 0.75 | - | ||
| 2021/6 | 11.5 | -0.55 | 9.3 | 67.89 | 44.08 | 34.64 | 0.79 | - | ||
| 2021/5 | 11.57 | -0.08 | 34.44 | 56.38 | 53.0 | 34.14 | 0.8 | 外銷戒癮含片之美國終端市場份額較去年同期大幅增加 | ||
| 2021/4 | 11.57 | 5.18 | 46.44 | 44.82 | 58.66 | 32.74 | 0.83 | 外銷戒癮含片之美國終端市場份額較去年同期大幅增加 | ||
| 2021/3 | 11.0 | 8.31 | 57.46 | 33.24 | 63.4 | 33.24 | 0.66 | 因去年第二季起新增東南亞市場業務、且旗下外銷戒癮含片之美國終端市場份額較去年同期大幅增加 | ||
| 2021/2 | 10.16 | -15.89 | 95.4 | 22.24 | 75.75 | 32.35 | 0.68 | 因去年第二季起新增東南亞市場業務、且旗下外銷戒癮含片之美國終端市場份額較去年同期大幅增加 | ||
| 2021/1 | 12.08 | 19.47 | 62.05 | 12.08 | 62.05 | 31.76 | 0.69 | 因去年第二季起新增東南亞市場業務、且旗下外銷戒癮含片之美國終端市場份額較去年同期大幅增加 | ||
| 2020/12 | 10.11 | 5.63 | -41.69 | 105.89 | 15.41 | 29.92 | 0.74 | - | ||
| 2020/11 | 9.57 | -6.45 | 31.47 | 95.78 | 27.46 | 30.01 | 0.74 | - | ||
| 2020/10 | 10.23 | 0.26 | 38.35 | 86.2 | 27.02 | 27.92 | 0.79 | - | ||
| 2020/9 | 10.21 | 36.45 | 67.93 | 75.97 | 25.64 | 28.85 | 0.59 | 主要係因外銷業務持續成長、今年4月起新增東南亞市場業務，及去年底取得之授權品項陸續上市，使得營收較去年同期大幅成長 | ||
| 2020/8 | 7.48 | -33.03 | 19.28 | 65.76 | 20.68 | 29.17 | 0.58 | - | ||
| 2020/7 | 11.17 | 6.14 | 49.78 | 57.82 | 19.9 | 30.29 | 0.56 | - | ||
| 2020/6 | 10.52 | 22.31 | 48.24 | 46.65 | 14.44 | 27.03 | 0.55 | - | ||
| 2020/5 | 8.6 | 8.84 | 26.59 | 36.13 | 4.69 | 23.49 | 0.63 | - | ||
| 2020/4 | 7.9 | 13.1 | 34.21 | 27.55 | -0.61 | 20.09 | 0.73 | - | ||
| 2020/3 | 6.99 | 34.4 | 16.82 | 19.64 | -10.01 | 19.64 | 0.66 | - | ||
| 2020/2 | 5.2 | -30.25 | -48.62 | 12.65 | -21.05 | 30.0 | 0.43 | - | ||
| 2020/1 | 7.45 | -57.01 | 26.17 | 7.45 | 26.17 | 0.0 | N/A | - | ||
| 2019/12 | 17.34 | 138.2 | 227.28 | 92.48 | 43.85 | 0.0 | N/A | 外銷業務成長，去年同期部分產品未上市，又戒癮含片新增終端客戶與美國數州學名藥轉換，需求放大，經銷商為增加供貨彈性遂備貨 |
